Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals (Q24236476)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20687097

17 June 2024

3

Nandi Siegfried

Nandi

Siegfried

1 reference

PubMed

20 October 2023

Alicen Spaulding

1

Alicen

Spaulding

1 reference

PubMed

20 October 2023

George W. Rutherford

series ordinal

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20687097

full work available at URL

17 June 2024

language of work or name

1 reference

4 August 2010

0 references

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD008651/fullpdf

1 reference

10.1002/14651858.CD008651

DOI

https://api.crossref.org/works/10.1002/14651858.CD008651

Cochrane Database of Systematic Reviews

17 June 2024

published in

0 references

cites work

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Effects of Potent Antiretroviral Therapy on Free Testosterone Levels and Fat-Free Mass in Men in a Prospective, Randomized Trial: A5005s, a Substudy of AIDS Clinical Trials Group Study 384

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008651

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD008651

0 references

Fatcat ID

release_i6aaty7sgff67olhhwijlvucxa

0 references